We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

354 hedge funds and large institutions have $6.43B invested in Bio-Rad Laboratories Class A in 2019 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 148 increasing their positions, 97 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 29

53% more repeat investments, than reductions

Existing positions increased: 148 | Existing positions reduced: 97

10% more capital invested

Capital invested by funds: $5.87B → $6.43B (+$562M)

7% more funds holding

Funds holding: 330354 (+24)

2.26% more ownership

Funds ownership: 75.91%78.17% (+2.3%)

36% less funds holding in top 10

Funds holding in top 10: 117 (-4)

69% less call options, than puts

Call options by funds: $9.75M | Put options by funds: $31.4M

Holders
354
Holders Change
+24
Holders Change %
+7.27%
% of All Funds
7.76%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.15%
New
54
Increased
148
Reduced
97
Closed
29
Calls
$9.75M
Puts
$31.4M
Net Calls
-$21.7M
Net Calls Change
-$37.2M
Name Holding Trade Value Shares
Change
Change in
Stake
GHCM
201
Glen Harbor Capital Management
California
$969K
SC
202
Sepio Capital
Utah
$906K +$53.2K +163 +6%
RCM
203
Riverhead Capital Management
Delaware
$888K
MS
204
Maven Securities
Jersey
$878K +$856K +2,623 New
AG
205
Advisor Group
Arizona
$851K +$79.9K +245 +11%
SM
206
Sciencast Management
New Jersey
$817K +$799K +2,450 New
SAM
207
Securian Asset Management
Minnesota
$803K +$5.87K +18 +0.8%
OI
208
Oakbrook Investments
Illinois
$782K +$767K +2,350 New
CGH
209
Crossmark Global Holdings
Texas
$764K -$33.9K -104 -4%
MCIM
210
Meadow Creek Investment Management
Georgia
$761K
FMW
211
Farr Miller & Washington
District of Columbia
$744K +$101K +311 +16%
SPC
212
Stewart & Patten Company
California
$732K
PSUF
213
People's United Financial
Connecticut
$712K -$5.22K -16 -0.7%
ProShare Advisors
214
ProShare Advisors
Maryland
$707K +$14K +43 +2%
Verition Fund Management
215
Verition Fund Management
Connecticut
$702K -$20.9K -64 -3%
CTC
216
Central Trust Company
Missouri
$686K +$666K +2,042 +10,210%
VRS
217
Virginia Retirement Systems
Virginia
$665K
SDIC
218
South Dakota Investment Council
South Dakota
$665K +$294K +900 +82%
AAP
219
Ardsley Advisory Partners
Connecticut
$665K +$652K +2,000 New
MSL
220
Mackay Shields LLC
New York
$648K +$635K +1,946 New
PIA
221
Piedmont Investment Advisors
North Carolina
$647K -$2.61K -8 -0.4%
LTFS
222
Ladenburg Thalmann Financial Services
Florida
$647K +$170K +521 +37%
HighTower Advisors
223
HighTower Advisors
Illinois
$642K +$93.3K +286 +17%
GCC
224
Guardian Capital (Canada)
Ontario, Canada
$639K +$626K +1,920 New
GCP
225
GSA Capital Partners
United Kingdom
$635K +$622K +1,907 New

BIO Hedge Fund Activity: Q3 2019 in Review

354 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2019, worth a combined $6.43B — up 9.6% from $5.87B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new BIO positions and 29 closed out — a net gain of 25 holders — while 148 added to existing stakes and 97 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $121M. The largest seller was Easterly Investment Partners, cutting an estimated $120M.

  • 354 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2019, up from 330 in Q2 2019.
  • Funds reported $6.43B of Bio-Rad Laboratories Class A stock for Q3 2019, up 9.6% quarter-over-quarter.
  • 54 funds opened new Bio-Rad Laboratories Class A positions in Q3 2019 and 29 closed out, a net change of +25 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2019 was Acadian Asset Management, an estimated $121M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2019 was Easterly Investment Partners, an estimated $120M sold.

Based on aggregated 13F filings for Q3 2019.